178 related articles for article (PubMed ID: 32068456)
1. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy.
Barata P; Swami U; Agarwal N
Expert Rev Anticancer Ther; 2020 Mar; 20(3):147-150. PubMed ID: 32068456
[No Abstract] [Full Text] [Related]
2. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
[TBL] [Abstract][Full Text] [Related]
4. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
Hoy SM
Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
[TBL] [Abstract][Full Text] [Related]
5. Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Basch E; Miladinovic B; Lopez-Gitlitz A; Chi KN
J Urol; 2021 Oct; 206(4):914-923. PubMed ID: 34039013
[TBL] [Abstract][Full Text] [Related]
6. The development of apalutamide for the treatment of prostate cancer.
Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
[TBL] [Abstract][Full Text] [Related]
7. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.
Wang B; Pan J; Zhang T; Ni X; Wei Y; Li X; Fang B; Hu X; Gan H; Wu J; Wang H; Ye D; Zhu Y
BMC Cancer; 2024 May; 24(1):643. PubMed ID: 38796422
[TBL] [Abstract][Full Text] [Related]
8. Apalutamide and its use in the treatment of prostate cancer.
Borno HT; Small EJ
Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
10. Apalutamide for the treatment of prostate cancer.
Rathkopf DE; Scher HI
Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
[TBL] [Abstract][Full Text] [Related]
11. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
12. Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy.
Aragon-Ching JB; Dreicer R
Expert Rev Anticancer Ther; 2020 Jun; 20(6):483-490. PubMed ID: 32406281
[TBL] [Abstract][Full Text] [Related]
13. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Iijima K; Nishimura K; Fujii K; Hatayama T; Aoyama J; Deprince K; Lopez-Gitlitz A; McCarthy S; Larsen JS; Li J; Chi KN
Int J Urol; 2021 Mar; 28(3):280-287. PubMed ID: 33295007
[TBL] [Abstract][Full Text] [Related]
14. Apalutamide: First Global Approval.
Al-Salama ZT
Drugs; 2018 Apr; 78(6):699-705. PubMed ID: 29626324
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
16. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].
Rexer H; Graefen M
Urologe A; 2017 Feb; 56(2):243-244. PubMed ID: 28144693
[No Abstract] [Full Text] [Related]
17. Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.
Condon B; Liskaser G; Thangasamy IA; Murphy DG
Curr Opin Urol; 2020 Jul; 30(4):620-622. PubMed ID: 31725005
[No Abstract] [Full Text] [Related]
18. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
Dror CM; Chi KN
Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
[TBL] [Abstract][Full Text] [Related]
19. Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer.
Tsao PA; Caram MEV
Cancer J; 2020; 26(1):76-82. PubMed ID: 31977389
[TBL] [Abstract][Full Text] [Related]
20. Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Zang Z; Wang Z; Chiong E
Int J Urol; 2022 Jun; 29(6):541. PubMed ID: 35384091
[No Abstract] [Full Text] [Related]
[Next] [New Search]